Clinical trial
Aripiprazole in the Treatment of Bipolar Depression
NCT00226317 · Cambridge Health Alliance, Other · Completed
Key facts
| NCT number | NCT00226317 |
|---|---|
| Title | Aripiprazole in the Treatment of Bipolar Depression |
| Official title | Phase 4 Study: An Open Prospective Study of the Safety and Effectiveness of Aripiprazole in the Treatment of Bipolar Depression |
| Lead sponsor | Cambridge Health Alliance, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Bipolar Disorder |
| Intervention type | Drug |
| Interventions | Aripiprazole |
| Enrollment | 20 |
| Start date | Apr 1, 2004 |
| Primary completion | Dec 1, 2007 |
| Completion | Feb 1, 2008 |
| First posted | Sep 27, 2005 |
| Last update posted | Apr 18, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: